Mabwell's Anti-ST2 Antibody Shows Promising COPD Exacerbation…

Event summary

Mabwell presented Phase Ib/IIa results for 9MW1911, an anti-ST2 monoclonal antibody, at ERS 2026, showing a 24-81% reduction in moderate-to-severe COPD exacerbations in mid-to-high dose groups.
The randomized, double-blind, placebo-controlled trial enrolled 80 participants with moderate-to-severe COPD, with doses ranging from 100 mg to 900 mg administered every 4 weeks.
9MW1911 demonstrated dose-proportional exposure and a favorable safety profile, with Phase III trial initiation expected by year-end 2026.
FDA cleared the IND application for a Phase IIa trial in the U.S., expanding the antibody's clinical development scope.

The big picture

Mabwell's positive Phase Ib/IIa results for 9MW1911 position it as a key player in the COPD treatment space, where reducing exacerbations remains a critical unmet need. The antibody's proprietary development and favorable safety profile could enhance Mabwell's standing in the biopharmaceutical industry, particularly in respiratory and aging-related diseases. The strategic move to expand into U.S. trials underscores the company's ambition to compete globally.

What we're watching

Clinical Progression: The pace at which Mabwell advances 9MW1911 into Phase III trials and secures regulatory approvals will determine its competitive positioning in the COPD treatment landscape.
Market Differentiation: Whether 9MW1911 can demonstrate superior efficacy and safety compared to existing therapies will influence its commercial potential.
Global Expansion: How Mabwell leverages the FDA clearance for U.S. trials to accelerate international clinical development and partnerships.